KalVista Pharmaceuticals is a public pharmaceutical company which has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
In May 2021 Occam placed Paul Audhya, MD as its CMO. Audhya has over 20 years of clinical development and global medical affairs leadership experience. He previously served as Senior Vice President, Global Medical Affairs at Arena Pharmaceuticals. Prior to Arena, Dr. Audhya held positions of increasing responsibility across all stages of drug development at Vertex Pharmaceuticals, Hospira, Reata Pharmaceuticals, Abbott Labs, Amgen, Bristol Myers Squibb and Janssen.
